Trial · NCT01283464
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
NCT01283464, Phase 2, Completed, Johns Hopkins University; results first posted 2013-08-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles. Trials, record NCT01283464. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01283464
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
- NCT number
- NCT01283464
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- Johns Hopkins University
- Conditions
- Photodamaged Skin, Wrinkles
- Interventions
- Retinol, Tretinoin
- First posted
- 2011-01-26
- Last updated
- 2016-04-04
- Results first posted
- 2013-08-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Global Photodamage Severity | Week 24 | A photonumeric scale for the assessment of cutaneous photodamage (CE Griffiths, et al). Five photographic standards (en face and 45 degrees oblique) illustrating increasing severity of photodamage (min=0, max=8) where 0=no damamge; 2=mild damage; 4=moderate damage; 6=moderate/severe damage; and grade 8=severe damage. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Global Photodamage Severity | Week 24 | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Global Photodamage Severity | Retinol | 4.8 | Standard Deviation 1.687 | units on a scale | |
| Global Photodamage Severity | Tretinoin | 5.45 | Standard Deviation 1.572 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Retinol | 12 | |
| Overall Study | STARTED | Tretinoin | 12 | |
| Overall Study | COMPLETED | Retinol | 10 | |
| Overall Study | COMPLETED | Tretinoin | 11 | |
| Overall Study | NOT COMPLETED | Retinol | 2 | |
| Overall Study | NOT COMPLETED | Tretinoin | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | inpatient admission for pneumonia | Respiratory, thoracic and mediastinal disorders | Retinol | 1 | 12 | 1 |
| serious | inpatient admission for pneumonia | Respiratory, thoracic and mediastinal disorders | Tretinoin | 0 | 12 | 0 |
| serious | inpatient admission for orthopedic surgery | Surgical and medical procedures | Retinol | 0 | 12 | 0 |
| serious | inpatient admission for orthopedic surgery | Surgical and medical procedures | Tretinoin | 1 | 12 | 1 |
| serious | inpatient admission for near syncopal episode | Gastrointestinal disorders | Retinol | 0 | 12 | 0 |
| serious | inpatient admission for near syncopal episode | Gastrointestinal disorders | Tretinoin | 1 | 12 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Retinol | ||
| Total, all-cause mortality | Tretinoin | ||
| Total, other adverse events | Retinol | 0 | 12 |
| Total, other adverse events | Tretinoin | 0 | 12 |
| Total, serious adverse events | Retinol | 1 | 12 |
| Total, serious adverse events | Tretinoin | 2 | 12 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35675051 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Retinol vs Tretinoin: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01283464
GET https://conductscience.org/api/trials/v1/NCT01283464/registered